Royal Fund Management LLC Purchases 20,625 Shares of Bristol Myers Squibb Company $BMY

Royal Fund Management LLC raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 51.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,467 shares of the biopharmaceutical company’s stock after purchasing an additional 20,625 shares during the period. Royal Fund Management LLC’s holdings in Bristol Myers Squibb were worth $3,261,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Range Financial Group LLC boosted its stake in Bristol Myers Squibb by 4.9% in the fourth quarter. Range Financial Group LLC now owns 15,974 shares of the biopharmaceutical company’s stock valued at $862,000 after acquiring an additional 747 shares during the last quarter. Lewis Asset Management LLC raised its position in shares of Bristol Myers Squibb by 7.0% during the 4th quarter. Lewis Asset Management LLC now owns 11,298 shares of the biopharmaceutical company’s stock valued at $609,000 after acquiring an additional 744 shares during the last quarter. Signature Wealth Management Group lifted its stake in shares of Bristol Myers Squibb by 2.2% in the 4th quarter. Signature Wealth Management Group now owns 83,525 shares of the biopharmaceutical company’s stock valued at $4,505,000 after purchasing an additional 1,832 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Bristol Myers Squibb by 7.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,038,430 shares of the biopharmaceutical company’s stock valued at $55,514,000 after purchasing an additional 67,783 shares during the period. Finally, Brookstone Capital Management boosted its position in shares of Bristol Myers Squibb by 0.8% in the 4th quarter. Brookstone Capital Management now owns 123,598 shares of the biopharmaceutical company’s stock worth $6,667,000 after purchasing an additional 985 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Phase 3 SCOUT‑HCM data for Camzyos (mavacamten) in adolescents showed efficacy and safety, increasing the drug’s addressable market and raising the chance of label expansion and incremental sales for BMY’s cardiovascular franchise. Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT‑HCM Trial
• Positive Sentiment: The FDA granted approval for BMY’s combination regimen in Hodgkin’s lymphoma (announced March 20), adding a near‑term revenue stream and supporting sentiment around the oncology portfolio. Bristol‑Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment
• Neutral Sentiment: Phase 4 data for Cobenfy (xanomeline+tropium) presented safety/tolerability data in switching patients, which could reshape long‑term revenue assumptions if follow‑on studies or real‑world switching data are favorable — outcome still uncertain for valuation impact. Cobenfy Phase 4 Data May Reframe Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Analyses highlight growth opportunities in the pancreatic adenocarcinoma market (projected high CAGR) where BMY is named among major players — long‑term tailwind but competitive landscape and timing of launches matter. Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR
• Neutral Sentiment: Several financial writeups point to BMY as an income/dividend name and note an upcoming ex‑dividend date; that can support demand from yield‑focused investors but doesn’t change fundamentals. Bristol‑Myers Squibb Looks Like A Good Stock, And It’s Going Ex‑Dividend Soon
• Negative Sentiment: Analyst coverage is mixed — roughly 60% of covering analysts have non‑bullish ratings even though the consensus price target implies limited upside, which could cap upside until guidance or earnings beat expectations and analysts raise targets. Bristol‑Myers Squibb Faces Mixed Analyst Sentiment

Analysts Set New Price Targets

A number of equities research analysts recently commented on BMY shares. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a report on Wednesday, December 3rd. Morgan Stanley restated an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Barclays began coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target for the company. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $61.41.

Bristol Myers Squibb Stock Performance

BMY stock opened at $59.76 on Tuesday. The business’s 50-day moving average price is $58.91 and its two-hundred day moving average price is $52.35. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm has a market cap of $122.01 billion, a PE ratio of 17.32, a P/E/G ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.